Find information on thousands of medical conditions and prescription drugs.

Factor VIII deficiency

Haemophilia A (also spelt Hemophilia A or Hæmophilia A) is a blood clotting disorder caused by a mutation of the factor VIII gene, leading to a deficiency in Factor VIII. It is the most common hemophilia. Inheritance is X-linked; hence, males are affected while females are carriers or very rarely display a mild phenotype. 1 in 10,000 males are affected. more...

Home
Diseases
A
B
C
D
E
F
Fabry's disease
Facioscapulohumeral...
Factor V Leiden mutation
Factor VIII deficiency
Fallot tetralogy
Familial adenomatous...
Familial Mediterranean fever
Familial periodic paralysis
Familial polyposis
Fanconi syndrome
Fanconi's anemia
Farber's disease
Fascioliasis
Fatal familial insomnia
Fatty liver
Febrile seizure
Fibrodysplasia ossificans...
Fibromatosis
Fibrosarcoma
Fibrosis
Fibrous dysplasia
Filariasis
Fissured tongue
Fitz-Hugh-Curtis syndrome
Flesh eating bacteria
Fluorosis
Focal dystonia
Foix-Alajouanine syndrome
Follicular lymphoma
Fountain syndrome
Fragile X syndrome
Fraser syndrome
FRAXA syndrome
Friedreich's ataxia
Frontotemporal dementia
Fructose intolerance
Fructose-1,6-bisphosphatase...
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Signs and symptoms

Hemophilia leads to a severely increased risk of bleeding from common injuries. The sites of bleeding are:

  • joints
  • muscles
  • digestive tract
  • brain

The muscle and joint haemorrhages are quite typical of haemophilia, while digestive tract and cerebral haemorrhages are also germane to other coagulation disorders.

Diagnosis

The diagnosis may be suspected as coagulation testing reveals an increased PTT in the context of a normal PT and bleeding time. The diagnosis is made in the presence of very low (<10 IU) levels of factor VIII. A family history is frequently present, although not essential. Nowadays, genetic testing may also be performed.

The most important differential diagnosis is that of hemophilia B (also known as Christmas disease) or von Willebrand disease. The former is usually considered if factor VIII levels are normal in a person with a haemophilia phenotype. The latter is excluded on routine testing for that condition.

A very small minority of patients has antibodies against factor VIII that impair its functioning. Management of these patients is more complicated (see below).

Therapy

Most haemophilia patients require regular supplementation with intravenous recombinant factor VIII. This is highly individually determined. Apart from "routine" supplementation, extra factor concentrate is given around surgical procedures and after trauma. In children, an easily accessible intravenous port (e.g. Port-a-Cath) may have to be inserted to minimise frequent traumatic intravenous cannulation.

Some may manage on desmopressin, if the clotting factor is still partially active.

A particular therapeutic conundrum is the development of "inhibitor" antibodies against factor VIII due to frequent infusions. These probably develop as the body recognises the factor VIII as foreign, as the body does not have its own "copy". The problem is that in these patients, factor VIII infusions are ineffective. Recently activated factor VII (NovoSeven®) has become available as a treatment for haemorrhage in patients with haemophilia and factor inhibitors.

Read more at Wikipedia.org


[List your site here Free!]


Increased Factor VIII Level as a Risk Factor for DVT - deep venous thrombosis
From American Family Physician, 2/15/01 by Jeffrey T. Kirchner

At least three published studies to date have found that an increased level of factor VIII is associated with venous thrombosis. The mechanism by which this occurs has not been determined. Treatment with oral anticoagulants can lessen the risk of thrombosis, although anticoagulant therapy may increase the risk of bleeding complications. Moreover, the optimal length of anticoagulation therapy has not been determined. Kyrle and colleagues attempted to determine whether an elevated level of factor VIII confers an increased risk of venous thromboembolic disease in patients who have sustained at least one thromboembolic event.

Patients enrolled were adults older than 18 years who had been treated with oral anticoagulants for at least three months after an episode of deep venous thrombosis, pulmonary embolism, or both. Patients whose events were related to cancer, surgery, pregnancy or trauma, and those with a history of protein S or protein C deficiency or hyperhomocystinemia were excluded.

Day 1 of the study was the day oral anticoagulation was discontinued. Three weeks later, patients were screened for deficiency of protein S, protein C and antithrombin, as well as for the presence of lupus anticoagulant. In addition, the level of factor VIII was checked at this time. Patients were seen at three-month intervals for the first year and then every six months. The primary end point was the recurrence of deep venous thrombosis or pulmonary embolism.

A total of 360 patients (189 women) was enrolled in the study. The mean age of the study subjects was 48 years, and the mean follow-up time after cessation of oral anticoagulation was 30 months. Forty-one percent of women in the study sustained the first episode of thromboembolism while they were taking oral contraceptives.

Thirty-eight patients had a recurrent event that included 24 episodes of deep venous thrombosis and 14 cases of pulmonary embolism. These patients had significantly higher levels of factor VIII (182 IU per dL versus 157 IU per dL) than those who did not have a recurrence. This remained a significant risk even after adjustment for age, sex, duration of anticoagulation, the presence of factor V Leiden, and the presence of the G20210A prothrombin mutation. In patients with a factor VIII level above the 90th percentile, the risk of recurrence was almost seven times greater than the risk in patients with normal levels. At two years, these patients had a 37 percent chance of recurrent deep venous thrombosis or pulmonary embolism compared with a 5 percent chance in patients whose level was below the 90th percentile.

The authors conclude that a high plasma level of factor VIII is a significant independent risk factor for recurrent venous thromboembolism. They recommend routine screening for factor VIII levels in patients who are being screened for thrombophilia. The risk of recurrence must be weighed against the risk of bleeding complications with anticoagulant therapy, which is about 1 to 2 percent annually.

EDITOR'S NOTE: The number of laboratory studies recommended for evaluating patients as part of a hypercoagulability work-up continues to grow. This study suggests that an assay for factor VIII be added to the panel of tests that includes protein S, protein C, antithrombin III, factor V Leiden and lupus anticoagulant.--J.T.K.

COPYRIGHT 2001 American Academy of Family Physicians
COPYRIGHT 2001 Gale Group

Return to Factor VIII deficiency
Home Contact Resources Exchange Links ebay